Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tool aims to revolutionize lung cancer screening

NCT ID NCT07408531

Diagnosis Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study is testing whether an artificial intelligence tool called Sybil can improve lung cancer screening by better predicting who is at risk. Researchers will analyze low-dose CT scans from 2,500 people aged 50-80 and compare AI results with current screening guidelines. The goal is to see if AI can catch more cancers earlier, especially in people not covered by standard recommendations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sybil Artificial Intelligence (AI) screening tool
What this could lead to
If successful, this could lead to more accurate and inclusive lung cancer screening, catching more cases early in people who currently fall outside standard guidelines.
What could go wrong
This is an early-stage observational study, not a treatment trial. The AI tool may not perform better than current methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2038

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 50-80 years at the time of consent * Meets at least one of the following LCS eligibility criteria: * USPSTF: ≥20 pack-years, currently smoke or quit ≤15 years ago. * Potter: 20 years of smoking, regardless of intensity * ACS: ≥20 pack-years, no restriction on quit time * Receiving or scheduled for LDCT through the UI Health Lung Screening Program. * Willing to view a short (approximately 2-minute) educational video that explains Sybil AI scoring and LCS, complete the Sybil AI survey (if selected), and/or provide blood samples (optional). * Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC IRB ICF and HIPAA authorization. * Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines. * As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study Exclusion Criteria: * Inability to undergo LDCT * Current diagnosis or history of lung cancer \< 5 years prior to study enrollment. * Life expectancy \<1 year * Active lung infection requiring systemic therapy * Vulnerable population, including prisoners and pregnant or nursing women, will not be enrolled due to radiation exposure from LDCT, which is contraindicated in pregnancy. * Other major comorbidity, as determined by the study PI * Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer screening are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer screening

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UI Health

    RECRUITING

    Chicago, Illinois, 60612, United States

  • UI Health 55th and Pulaski Health Collaborative

    RECRUITING

    Chicago, Illinois, 60629, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.